Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

Clinical trial NCT00056173 · COMPLETED

Trial details

NCT number: NCT00056173
Sponsor: Aptose Biosciences Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carcinoma, Renal Cell Metastases, Neoplasm

Start date: 2002-03-01
Primary completion: 2004-12-01
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.